Effectiveness of MRNA BNT162b2 COVID-19 Vaccine Up to 6 Months in a Large Integrated Health System in the USA: a Retrospective Cohort Study

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2021 Oct 7

PMID 34619098

Citations 688

Authors

Sara Y Tartof

Jeff M Slezak

Heidi Fischer

Vennis Hong

Bradley K Ackerson

Omesh N Ranasinghe

Timothy B Frankland

Oluwaseye A Ogun

Joann M Zamparo

Sharon Gray

Srinivas R Valluri

Kaije Pan

Frederick J Angulo

Luis Jodar

John M McLaughlin

Affiliations

Soon will be listed here.

Abstract

Background: Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.

Methods: In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584.

Findings: Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29-61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72-74) and against COVID-19-related hospital admissions was 90% (89-92). Effectiveness against infections declined from 88% (95% CI 86-89) during the first month after full vaccination to 47% (43-51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85-97]) but declined to 53% [39-65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95-99), but waned to 67% (45-80) at 4-5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84-96]) up to 6 months.

Interpretation: Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.

Funding: Pfizer.

Citing Articles

SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography.

Ma J, Kaniper S, Vabishchevich Y, Nyantakyi N, Lynch D, Chun F Sci Rep. 2025; 15(1):6577.

PMID: 39994387 PMC: 11850742. DOI: 10.1038/s41598-025-90730-9.

Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA.

Robinson L, Feting A, Isozaki I, Seyfert-Morgolis V, Jay M, Kim E BMJ Open. 2025; 15(2):e084408.

PMID: 39987006 PMC: 11848656. DOI: 10.1136/bmjopen-2024-084408.

Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.

Chen Z, Xie F, Zhang H, Li D, Zhang S, Zhang M Front Public Health. 2025; 13:1478627.

PMID: 39935878 PMC: 11811089. DOI: 10.3389/fpubh.2025.1478627.

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

Awadalla M, AlRawi H, Henawi R, Barnawi F, Alkadi H, Alyami A Front Immunol. 2025; 16:1526444.

PMID: 39911379 PMC: 11794813. DOI: 10.3389/fimmu.2025.1526444.

Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.

Blanco J, Trinite B, Puig-Barbera J Influenza Other Respir Viruses. 2025; 19(1):e70076.

PMID: 39871737 PMC: 11773156. DOI: 10.1111/irv.70076.

References

Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H . Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March.... MMWR Morb Mortal Wkly Rep. 2021; 70(34):1163-1166. PMC: 8389386. DOI: 10.15585/mmwr.mm7034e3. View

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G . Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022; 7(1):14. PMC: 8795435. DOI: 10.1038/s41541-022-00432-w. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Koebnick C, Langer-Gould A, Gould M, Chao C, Iyer R, Smith N . Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16(3):37-41. PMC: 3442759. DOI: 10.7812/TPP/12-031. View

Liu J, Liu Y, Xia H, Zou J, Weaver S, Swanson K . BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021; 596(7871):273-275. DOI: 10.1038/s41586-021-03693-y. View

Hall V, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A . COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397(10286):1725-1735. PMC: 8064668. DOI: 10.1016/S0140-6736(21)00790-X. View

Tenforde M, Self W, Naioti E, Ginde A, Douin D, Olson S . Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(34):1156-1162. PMC: 8389395. DOI: 10.15585/mmwr.mm7034e2. View

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

10.

Haas E, McLaughlin J, Khan F, Angulo F, Anis E, Lipsitch M . Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2021; 22(3):357-366. PMC: 8457761. DOI: 10.1016/S1473-3099(21)00566-1. View

11.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

12.

Singer S, Angulo F, Swerdlow D, McLaughlin J, Hazan I, Ginish N . Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. EClinicalMedicine. 2021; 42:101190. PMC: 8628463. DOI: 10.1016/j.eclinm.2021.101190. View

13.

Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias C . BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021; 385(5):472-474. PMC: 8133696. DOI: 10.1056/NEJMc2106083. View

14.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View

15.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

16.

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

17.

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

18.

Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P, Hasan M . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021; 27(9):1614-1621. DOI: 10.1038/s41591-021-01446-y. View

19.

Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J . Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December.... MMWR Morb Mortal Wkly Rep. 2021; 70(13):495-500. PMC: 8022879. DOI: 10.15585/mmwr.mm7013e3. View

20.

Callow K, Parry H, Sergeant M, Tyrrell D . The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990; 105(2):435-46. PMC: 2271881. DOI: 10.1017/s0950268800048019. View